

Amendments to the claims:

This listing of the claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

Claim 1 to Claim 24 (Canceled)

25. (New) A medicament for allergen-specific immunotherapy, said medicament containing a therapeutically effective amount of microparticles in a pharmaceutical formulation, said microparticles consisting essentially of:
 - (a) a three dimensionally cross-linked agarose bead; and
 - (b) a purified recombinant polypeptide allergen derived from plant pollen bound to said bead by means of a covalent bond between said cross-linked agarose and a reactive group of said allergenwherein said medicament is capable of inducing a strong allergen-specific IgG response comparable to that of an equivalent Alum-bound allergen with less granulomatous tissue reactions as compared to said Alum-bound allergen.
26. (New) The medicament according to claim 25, wherein the bead is activated spherical agarose.
27. (New) The medicament according to claim 25, wherein the allergen is a grass pollen allergen.
28. (New) The medicament according to claim 25, wherein the allergen is a timothy grass pollen allergen.
29. (New) The medicament according to claim 25, wherein the allergen is the Phl p 5b allergen of SEQ ID NO: 1.
30. (New) The medicament according to claim 25, wherein the microparticles have a mean diameter that ranges from 0.1 μm to 10 μm .
31. (New) The medicament according to claim 25, wherein the microparticles have a mean diameter that ranges from 0.5 μm to 5 μm .

32. (New) The medicament according to claim 25, wherein the microparticles have a mean diameter on the order of 2 μm .
33. (New) The medicament according to claim 25, wherein the bead is cyanogen bromide-activated spherical agarose and the allergen is the Phl p 5b allergen of SEQ ID NO: 1.
34. (New) The medicament according to claim 25, wherein the pharmaceutical formulation is selected from the group consisting of an injectable solution, rectal foam, nasal spray, ointment and plaster.
35. (New) The medicament according to claim 25, wherein said pharmaceutical formulation comprises a parenteral solution.